阿哌沙班与利伐沙班治疗上肢深静脉血栓的疗效与安全性
本研究基于Mayo Clinic VTE注册队列,纳入210例急性上肢深静脉血栓患者,其中63例接受阿哌沙班、39例接受利伐沙班、108例接受低分子肝素和/或华法林治疗。3个月随访显示,直接口服抗凝药与低分子肝素/华法林在复发性VTE、大出血及临床相关非大出血方面无显著差异,提示阿哌沙班或利伐沙班治疗上肢深静脉血栓可能同样安全有效。
要点
- 阿哌沙班或利伐沙班治疗上肢深静脉血栓的复发性VTE与大出血风险与华法林/低分子肝素相当
- 51%为上肢深静脉血栓为导管相关,60%患者合并恶性肿瘤
核心结论
- 阿哌沙班或利伐沙班治疗急性上肢深静脉血栓可能和低分子肝素/华法林一样安全有效。
研究设计与样本
- 共纳入210例急性上肢深静脉血栓患者,其中阿哌沙班63例、利伐沙班39例、低分子肝素和/或华法林108例。
主要发现
- 51%患者为导管相关上肢深静脉血栓,60%合并恶性肿瘤,14%合并肺栓塞。
关键数值与推荐
- 复发性VTE、大出血、临床相关非大出血和死亡每3个月评估一次。
临床怎么用
- 对于急性上肢深静脉血栓患者,可考虑使用阿哌沙班或利伐沙班作为低分子肝素/华法林的替代抗凝方案。
局限性
- 本研究为前瞻性队列研究,非随机对照试验,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized controlled trials leading to the approval of apixaban and rivaroxaban for venous thromboembolism (VTE) did not include patients with upper extremity deep vein thrombosis (UE-DVT). We sought to evaluate the safety and effectiveness of rivaroxaban and apixaban for the treatment of acute UE-DVT. Consecutive patients with VTE enrolled into the Mayo Clinic VTE Registry, between March 1, 2013 and December 31, 2019, were followed prospectively. Clinical, demographic and imaging data were collected at the time of study recruitment. Patients with a diagnosis of acute UE-DVT who received rivaroxaban, apixaban, LMWH or warfarin were included. Recurrent VTE, major bleeding, clinical-relevant non-major bleeding (CRNMB), and death were assessed at 3-month intervals. During the study period, 210 patients with acute UE-DVT were included; 63 were treated with apixaban, 39 with rivaroxaban, and 108 with LWMH and/or warfarin. Overall 51% had catheter-associated UE-DVT, 60% had a diagnosis of malignancy, and 14% had concurrent pulmonary embolism. Malignancy was more common in patients treated with LMWH/warfarin (67% vs 52%, P = .03). At 3 months of follow up, one (0.9%) recurrent VTE occurred in a patient treated with LMWH/warfarin and one (1.0%) patient treated with apixaban or rivaroxaban (P = .97). Major bleeding occurred in three patients treated with LMWH/warfarin, and in none of those treated with apixaban or rivaroxaban (P = .09). Clinical-relevant non-major bleeding occurred in one patient (0.9%) treated with LWMH/warfarin and two patients (2.0%) treated with apixaban or rivaroxaban (P = .53). Treatment of UE-DVT with apixaban or rivaroxaban appears to be as safe and effective as LMWH/warfarin.
引用
- Houghton DE, Casanegra AI, Peterson LG, et al. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. Am J Hematol. 2020. PMID: 32267011. doi:10.1002/ajh.25820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。